191 related articles for article (PubMed ID: 22362133)
1. Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors.
Chlopicki S; Lomnicka M; Fedorowicz A; Grochal E; Kramkowski K; Mogielnicki A; Buczko W; Motterlini R
Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):641-50. PubMed ID: 22362133
[TBL] [Abstract][Full Text] [Related]
2. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet Effect of Carbon Monoxide Is Mediated by NAD
Kaczara P; Sitek B; Przyborowski K; Kurpinska A; Kus K; Stojak M; Chlopicki S
Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2376-2390. PubMed ID: 32787519
[TBL] [Abstract][Full Text] [Related]
5. CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule.
Motterlini R; Sawle P; Hammad J; Bains S; Alberto R; Foresti R; Green CJ
FASEB J; 2005 Feb; 19(2):284-6. PubMed ID: 15556971
[TBL] [Abstract][Full Text] [Related]
6. Positive inotropic effects of carbon monoxide-releasing molecules (CO-RMs) in the isolated perfused rat heart.
Musameh MD; Fuller BJ; Mann BE; Green CJ; Motterlini R
Br J Pharmacol; 2006 Dec; 149(8):1104-12. PubMed ID: 17057755
[TBL] [Abstract][Full Text] [Related]
7. Distinct Pharmacological Properties of Gaseous CO and CO-Releasing Molecule in Human Platelets.
Kaczara P; Przyborowski K; Mohaissen T; Chlopicki S
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808315
[TBL] [Abstract][Full Text] [Related]
8. Investigation into the mechanism(s) of antithrombotic effects of carbon monoxide releasing molecule-3 (CORM-3).
Soni H; Jain M; Mehta AA
Thromb Res; 2011 Jun; 127(6):551-9. PubMed ID: 21376373
[TBL] [Abstract][Full Text] [Related]
9. [Study of exogenous carbon monoxide-releasing molecules 2 on endotoxin/lipopolysaccharide-induced abnormal activation of platelets of healthy human donors].
Liu D; Zhuang M; Zhang J; Chen J; Sun B
Zhonghua Shao Shang Za Zhi; 2015 Oct; 31(5):354-60. PubMed ID: 26714404
[TBL] [Abstract][Full Text] [Related]
10. A comparison of multifunctional donors of carbon monoxide: Their anticoagulant, antioxidant, anti-aggregatory and cytotoxicity activities in an in vitro model.
Adach W; Olas B
Nitric Oxide; 2020 Apr; 97():20-26. PubMed ID: 32006712
[TBL] [Abstract][Full Text] [Related]
11. Renal vascular responses to CORM-A1 in the mouse.
Ryan MJ; Jernigan NL; Drummond HA; McLemore GR; Rimoldi JM; Poreddy SR; Gadepalli RS; Stec DE
Pharmacol Res; 2006 Jul; 54(1):24-9. PubMed ID: 16524742
[TBL] [Abstract][Full Text] [Related]
12. Temporal inhibition of mouse mammary gland cancer metastasis by CORM-A1 and DETA/NO combination therapy.
Porshneva K; Papiernik D; Psurski M; Łupicka-Słowik A; Matkowski R; Ekiert M; Nowak M; Jarosz J; Banach J; Milczarek M; Goszczyński TM; Sieńczyk M; Wietrzyk J
Theranostics; 2019; 9(13):3918-3939. PubMed ID: 31281522
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.
Harmon S; Inkielewicz-Stepniak I; Jones M; Ledwidge M; Santos-Martinez MJ; Medina C; Radomski MW; Gilmer JF
J Pharm Pharmacol; 2012 Jan; 64(1):77-89. PubMed ID: 22150675
[TBL] [Abstract][Full Text] [Related]
14. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.
Crane MS; Rossi AG; Megson IL
Br J Pharmacol; 2005 Mar; 144(6):849-59. PubMed ID: 15685209
[TBL] [Abstract][Full Text] [Related]
15. Astrocyte-produced carbon monoxide and the carbon monoxide donor CORM-A1 protect against cerebrovascular dysfunction caused by prolonged neonatal asphyxia.
Parfenova H; Pourcyrous M; Fedinec AL; Liu J; Basuroy S; Leffler CW
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H978-H988. PubMed ID: 30028198
[TBL] [Abstract][Full Text] [Related]
16. Suppressive effect of CORM-2 on LPS-induced platelet activation by glycoprotein mediated HS1 phosphorylation interference.
Liu D; Liang F; Wang X; Cao J; Qin W; Sun B
PLoS One; 2013; 8(12):e83112. PubMed ID: 24376647
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of carbon monoxide-releasing molecules.
Motterlini R; Mann BE; Foresti R
Expert Opin Investig Drugs; 2005 Nov; 14(11):1305-18. PubMed ID: 16255672
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets.
Turnbull CM; Cena C; Fruttero R; Gasco A; Rossi AG; Megson IL
Br J Pharmacol; 2006 Jun; 148(4):517-26. PubMed ID: 16702997
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
